Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study

• DOI: 10.1111/all.16334
• Publication Date: 2024-10-08T16:36:29Z
• Authors: R. Soegiharto; M. Alizadeh Aghdam; J. A. Sørensen; E. van Lindonk; F. Bulut Demir; N. Mohammad Porras; Y. Matsuo; L. Kiefer; A. C. Knulst; M. Maurer; C. Ritchie; M. Rudenko; E. Kocatürk; R. F. J. Criado; S. Gregoriou; T. Bobylev; A. Kleinheinz; S. Takahagi; M. Hide; A. M. Giménez‐Arnau; A. Salman; R. Oztas Kara; B. S. Dikicier; M. B. A. van Doorn; S. F. Thomsen; J. M. P. A. van d...; H. Röckmann
• Keywords: Omalizumab; Discontinuation

Abstract Background Long‐term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking. Objective To evaluate effectiveness, safety, estimated treatment duration its predictors, as well differences between CIndU subtypes, a long‐term cohort. Methods A multinational multicenter study was conducted at 14 specialized centres (UCAREs), including all patients ever treated with from 2009 until July 2022. Kaplan–Meier survival regression analyses were performed. Results Across 234 (55% female; mean age 37 years), 76% ( n = 178) had standalone 24% 56) predominant plus minor CSU, an observation period up to 13 years. Most (73%, 145/200 available response) complete/good response treatment, without significant subtypes. Sixty‐two (26%) discontinued omalizumab; due well‐controlled disease (47%, 29), ineffectiveness (34%, 21), side effects (3%, 2), combination 2) other reasons (13%, 8). The median exceeded 5 years (54% drug years) mostly determined by disease. Higher predicted lower chance discontinue (HR 0.969, 95%CI 0.945–0.995). subtype presence CSU not related time discontinuation any reason. Conclusion Omalizumab is highly effective safe patients, long mainly reflecting duration. Our show omalizumab's high potential support clinical use these patients.